218 related articles for article (PubMed ID: 26499382)
1. Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
Yamazaki N; Kiyohara Y; Kudoh S; Seki A; Fukuoka M
Int J Clin Oncol; 2016 Apr; 21(2):248-253. PubMed ID: 26499382
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Nakagawa K; Kudoh S; Ohe Y; Johkoh T; Ando M; Yamazaki N; Seki A; Takemoto S; Fukuoka M
J Thorac Oncol; 2012 Aug; 7(8):1296-303. PubMed ID: 22610257
[TBL] [Abstract][Full Text] [Related]
3. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
4. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
5. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
[TBL] [Abstract][Full Text] [Related]
6. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
8. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Yoshioka H; Komuta K; Imamura F; Kudoh S; Seki A; Fukuoka M
Lung Cancer; 2014 Nov; 86(2):201-6. PubMed ID: 25280386
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
11. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Bidoli P; Cortinovis DL; Colombo I; Crippa A; Cicchiello F; Villa F; Cazzaniga ME; Altomare G
J Thorac Oncol; 2010 Oct; 5(10):1662-3. PubMed ID: 20871265
[TBL] [Abstract][Full Text] [Related]
12. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Lynch TJ; Fenton D; Hirsh V; Bodkin D; Middleman EL; Chiappori A; Halmos B; Favis R; Liu H; Trepicchio WL; Eton O; Shepherd FA
J Thorac Oncol; 2009 Aug; 4(8):1002-9. PubMed ID: 19633475
[TBL] [Abstract][Full Text] [Related]
16. The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Giuliani J; Marzola M
Cutan Ocul Toxicol; 2013 Sep; 32(3):248-51. PubMed ID: 23368942
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Takahashi T; Yamamoto N; Nukiwa T; Mori K; Tsuboi M; Horai T; Masuda N; Eguchi K; Mitsudomi T; Yokota S; Segawa Y; Ichinose Y; Fukuoka M; Saijo N
Anticancer Res; 2010 Feb; 30(2):557-63. PubMed ID: 20332470
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Mita AC; Papadopoulos K; de Jonge MJ; Schwartz G; Verweij J; Mita MM; Ricart A; Chu QS; Tolcher AW; Wood L; McCarthy S; Hamilton M; Iwata K; Wacker B; Witt K; Rowinsky EK
Br J Cancer; 2011 Sep; 105(7):938-44. PubMed ID: 21878940
[TBL] [Abstract][Full Text] [Related]
19. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
Deplanque G; Gervais R; Vergnenegre A; Falchero L; Souquet PJ; Chavaillon JM; Taviot B; Fraboulet G; Saal H; Robert C; Chosidow O;
J Am Acad Dermatol; 2016 Jun; 74(6):1077-85. PubMed ID: 26946985
[TBL] [Abstract][Full Text] [Related]
20. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
